Last reviewed · How we verify
octenisept®
Octenisept is an antimicrobial solution that disrupts bacterial and fungal cell membranes through a combination of octenidine and phenoxyethanol, providing rapid broad-spectrum antiseptic activity.
Octenisept is an antimicrobial solution that disrupts bacterial and fungal cell membranes through a combination of octenidine and phenoxyethanol, providing rapid broad-spectrum antiseptic activity. Used for Skin antisepsis and disinfection, Wound irrigation and cleansing, Oral and pharyngeal antisepsis.
At a glance
| Generic name | octenisept® |
|---|---|
| Sponsor | Schülke & Mayr GmbH |
| Drug class | Antiseptic/Antimicrobial solution |
| Modality | Small molecule |
| Therapeutic area | Dermatology/Infection Prevention |
| Phase | FDA-approved |
Mechanism of action
Octenidine is a cationic surfactant that damages microbial cell membranes and denatures proteins, while phenoxyethanol enhances antimicrobial efficacy. Together, these agents provide rapid bactericidal and fungicidal activity against a wide range of gram-positive and gram-negative bacteria, as well as fungi and some viruses, making it effective for skin and wound antisepsis.
Approved indications
- Skin antisepsis and disinfection
- Wound irrigation and cleansing
- Oral and pharyngeal antisepsis
- Prevention of surgical site infections
Common side effects
- Local irritation or burning sensation
- Allergic contact dermatitis
- Transient erythema
Key clinical trials
- Hyaluronic Acid and Octenidine Gel as an Adjunct to Non-surgical Periodontal Treatment (NA)
- Pocket-X Gel Non-surgical Periodontal Therapy (NA)
- Effectiveness of an Antimicrobial Agent for Preoperative Skin Preparation (PHASE2)
- Oleogel-S10 Versus Standard of Care in Healing of Grade 2a Burn Wounds (PHASE3)
- Study to Evaluate the Efficacy of Octenisept® in Patients With Chronic Wounds (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- octenisept® CI brief — competitive landscape report
- octenisept® updates RSS · CI watch RSS
- Schülke & Mayr GmbH portfolio CI